morphosys ag biopharmaceutical company founded company headquartered near munich germany wholly owned subsidiary morphosys us inc boston us company various antibody protein peptide technologies uses discover develop proprietary partnered drug candidates company drugs wider pipeline investigated variety many developed partnership pharma biotech companies morphosys also proprietary pipeline focus cancer autoimmune diseases morphosys ag listed frankfurt stock exchange us nasdaq stock exchange company founded morphosys listed frankfurt stock exchange ticker symbol mor morphosys novartis entered strategic partnership research development biopharmaceuticals expanded additional discovery partnerships included bayer roche centocor janssen biotech schering ag pfizer company first proprietary antibody otilimab entered clinical following publication promising results rheumatoid arthritis morphosys signed license agreement glaxosmithkline glaxosmithkline initiated phase clinical development program otilimab morphosys signed license agreement xencor inc july first morphosys platform drugs received us marketing approval guselkumab brand name tremfya developed commercialized janssen biotech subsidiary johnson johnson first approved treatment moderatetosevere plaque psoriasis united states european union april following us initial public offering company raised million american depositary shares morphosys began trading nasdaq stock exchange also symbol company established wholly owned us subsidiary morphosys us inc december based positive clinical trial results company submitted biologics license application bla fda tafasitamab combination lenalidomide treatment relapsedrefractory diffuse large bcell submission accepted filing february decision filing expected august january morphosys incyte corporation signed collaboration license agreement global development commercialization march agreement received antitrust clearance thus became march morphosys announced fda accepted biologics license application bla filing granted priority review tafasitamab setting prescription drug user fee act pdufa goal date august july monjuvi tafasitamabcxix approved us fda combination lenalidomide medical treatment adult patients relapsed refractory diffuse large bcell lymphoma dlbcl otherwise specified including dlbcl arising low grade lymphoma eligible autologous stem cell transplant december morphosys drug candidates developed morphosys pharmaceutical companies clinical development two antibodies developed morphosys already approved marketed tafasitamab humanized monoclonal antibody directed clinical development treatment bcell tafasitamab evaluated several clinical trials alone combination anticancer felzartamab humanized monoclonal antibody directed treatment membranous nephropathy autoimmune disease affecting morphosys entered regional licensing agreement imab biopharma develop commercialize felzartamab called imab greater felzartamab currently investigation imab three clinical otilimab fully human monoclonal antibody directed program outlicensed otilimab currently investigation phase trial rheumatoid arthritis started july march morphosys announced company would end preclinical research programs cease related activities according press release step justified challenges pharmaceutical market forcing company optimize cost structure focus resources oncology products mid late stage morphosys discovered number antibody technologies use drug development morphosys main technology hucal human combinatorial antibody library collection ten billion fully human antibodies form phage display bank system another technology recently developed okapy bispecific antibody technology morphosys okapy technology new proprietary bispecific antibody format hysicochemical properties simplify development largescale production httpsenwikipediaorgwikimorphosys